BioNTech’s ASCO Double Play: A €500 Million Cost Target and a Pipeline Under the Microscope
24.05.2026 - 13:05:03 | boerse-global.de
BioNTech enters a defining week with twin pressures: convincing investors its oncology pivot is working and proving it can tighten the purse strings. On the world’s largest cancer congress, ASCO in Chicago, the Mainz-based company will unveil clinical data from late-stage studies, while simultaneously mapping out a plan to slash annual spending by half a billion euros by 2029.
Between 29 May and 2 June, the company will present two oral presentations and four poster sessions. The spotlight falls on two lead candidates. For Pumitamig, a bispecific antibody, BioNTech is delivering interim data from a lung cancer study – the third global dataset to test the drug in combination with chemotherapy. Separately, survival figures for Gotistobart in platinum-resistant ovarian cancer are also on the agenda. The deeper ADC pipeline includes updates on programmes targeting advanced solid tumours, prostate cancer and endometrial cancer.
The financial backdrop gives the data drop extra weight. In the first quarter, BioNTech posted a net loss of nearly €532 million, while research and development spending climbed to €557 million. The company is burning cash to build a broad oncology platform, running more than 25 late-stage clinical trials. Yet management insists the balance sheet can handle the strain: liquid assets stand at almost €17 billion, and full-year revenue guidance remains steady at just over €2 billion. A multi-billion-euro share buyback programme is also in place to underpin the stock.
Should investors sell immediately? Or is it worth buying BioNTech?
To keep the transformation on track without draining reserves, BioNTech is streamlining production. Annual cost savings of around €500 million are targeted by 2029. The message is clear: the company wants to show it can scale up oncology without letting expenses run wild.
The stock has felt the pressure. At Friday’s close of €79.50, the shares are down roughly 15% over the past month and trading well below their long-term average. The technical picture remains fragile, and failure at ASCO could bring the recent low of €72.50 back into play.
The week is also shortened for US investors – Wall Street is closed on Monday for Memorial Day, leaving a tight window before the conference kicks off. Any positive surprise in the efficacy data, particularly in prostate and endometrial cancers, would validate the ADC push. Disappointing results, however, would shift attention squarely back to the high cash burn rate and the ambitious cost-cutting plan.
Ad
BioNTech Stock: New Analysis - 24 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
